Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
123I-mIBG Scintigraphy in Neuroblastoma and Phaeochromocytoma
NCT00126412Phase 3Completed
- Sponsor
- GE HealthCare
- Start
- Aug 2005
- Primary completion
- Sep 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of Iobenguane I-123 in neuroblastoma and pheochromocytoma, sponsored by GE HealthCare. Primary endpoints: Sensitivity of 123I-mIBG planar scintigraphy and Specificity of 123I-mIBG planar scintigraphy. Started Aug 2005; status: completed.
02
Drugs
Iobenguane I-123
03
Conditions
neuroblastomapheochromocytoma
Beyond the preview
Go deeper on NCT00126412.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00126412.